


Positive & negative inflammatory signals in the vascular wall



Young-Guen Kwon

**Vascular genomics Lab., Dept. of Biochemistry
Yonsei University**


Formation of a vascular network

Two processes are responsible for the formation of new blood vessels:


I. Vasculogenesis and Angiogenesis

Vasculogenesis: *in situ* formation of blood vessels from progenitor endothelial cells or angioblasts

Angiogenesis: formation of new blood vessels from preexisting blood vessels



Structure of Blood Vessel



Therapeutic angiogenesis

Ways for treating myocardial ischemia and peripheral vascular disease

Cell therapy for ischemia

Gene or protein therapy

EPC

Endothelial progenitor cell

VEGF

bFGF


Will any **single growth factor** or **stem cell therapy**

be the “**magic bullet**” to cure vascular disease?

>>> **Combination therapy?**

Therapeutic Angiogenesis (Gene or protein therapy)

What to deliver?



Cardiovascular Research 2005

Clinical trials of angiogenic therapy

| Protein | Trial type | N | Delivery |
|------------------------|-----------------|-----|---|
| FGF1 | Phase I, OL | 20 | Safe 41 Capillary blush at injection site |
| FGF2 | Phase I, OL | 30 | Hypotension at high dosages Dilatation of epicardial coronaries |
| FGF2 | Phase II, DBR | 337 | Safe/ No effect on ETT or SPECT Short-term improvement in symptoms compared to placebo |
| VEGF- A ₁₆₅ | Phase I, OL | 15 | Hypotension at low dosages Reduced SPECT defect size |
| VEGF- A ₁₆₅ | Phase II, DBR | 165 | No improvement in ETT, symptoms, or SPECT compared to controls |
| GM-CSF | Phase I/II, DBR | 21 | Improved collateral flow index in the GM-CSF group |

What are the risks?


- Aberrant Vascular Proliferation in Nontargeted Tissues
- Increased Vascular Permeability and Inflammation
- Induction of the Development of Functionally Abnormal Blood Vessels
- Triggering Growth of Neoplasms
- Increase in Atherosclerotic Plaque Mass and Instability
- Vasodilatation and Hypotension During Short-Term Administration
- Hazards Associated With Viral Vectors
- Hazards Associated With Direct Myocardial Delivery

Molecular link between angiogenesis and inflammation ?

>> Pro- and Anti-Inflammatory Signals Acting on Vascular Cells <<

| Mediators | Proinflammatory Signals | Anti-Inflammatory Signals |
|---------------------------|--|---|
| Cytokines | TNF, IL-1, IL-8, IFN-γ, Oncostatin M, IL-4, IL-13 | TGF-β, IL-10, IL-1ra, IL-13 |
| Angiogenic factors | VEGF, TRANCE | Angiopoietin-1 |
| Growth factors | PDGF | FGF, HGF |
| Vasoactive agents | Angiotensin II, endothelin | NO |
| Neuropeptides | Substance P | |
| Nuclear receptors | | PPARs |
| Mechanical forces | Stretch | Shear stress |
| Other | LPS, phobol esters, thrombin | HDL, n3-fatty acids |

NF- κ B; a key molecule of vascular inflammation



Vascular Inflammation

- a basic pathological mechanism that underlies **atherosclerosis**, **ischemia/reperfusion**, **rheumatoid arthritis**, **psoriasis**, **restenosis**, and **bronchial asthma**.

> Inflammatory process

The inflammatory process requires extravasation of leukocytes from the microvasculature at sites of inflammation or injury

- **Increased endothelial permeability**
- **Up-regulation of leukocyte adhesion molecules**
- **Up-regulation of endothelial adhesion molecules (ICAM & VCAM-1)**
- **Migration of leukocytes into the artery wall**


> Potential makers of Vascular Inflammation

Cellular adhesion molecules
Intracellular adhesion molecule-1
Vascular cellular adhesion molecule-1
Selectins
Chemokines
Monocyte chemoattractant protein-1
Cytokines
Interleukins 1, 6, 10, 18
Tumor necrosis factor- α
Proteases
Matrix metalloproteinases
Accessory signaling markers
CD40/CD40L
Acute phase proteins
C-reactive protein


TRANCE, TNF-related activation-induced cytokine

- also called **ODF**, **OPGL**, and **RANKL**
- exists either in a cell-bound form or a truncated ectodomain variant cleaved by TACE
- The biological function from the phenotype of RANKL-deficient mice
 - > *osteoclast functions and bone remodeling*
 - > *immune cell cross-talks, dendritic cell survival, and lymph node organogenesis.*
 - > *Mammary gland development*

RANK, Receptor activator of NF- κ B



OPG, Osteoprotegerin





TRANCE in the vascular system



- Prominent expression of TRANCE in the vascular cells *in vitro* and *in vivo*
- Expression of RANK in endothelial cells
 - >> up-regulation of RANK by VEGF in endothelial cells (JBC 2003)
- A potential risk factor for progressive atherosclerosis and cardiovascular disease
 - >> mice deficient in OPG exhibit arterial calcification in addition to early onset osteoporosis
- TRANCE in angiogenesis and vascular inflammation
 - >> induced angiogenesis *in vitro* and *in vivo* (JBC 2002)

Soluble TRANCE Induces Angiogenesis *in Vivo*

Chicken Chorioallantoic Membrane Assay




Mouse Matrigel plug assay




TRANCE fails to promote angiogenesis in eNOS-knock out mice in vivo


A




B






C



D






TRANCE increases monocyte adhesiveness and transendothelial migration of leukocyte *in vivo*




TRANCE induces **Vascular permeability** *in vivo*

; impairment in eNOS-deficient mice





Schematic diagram of potential expression, regulation, and function of RANKL, RANK, and OPG in atherosclerotic vascular calcification.



Elevated level of TRANCE in the vasculature may be importantly involved in the pathogenesis of atherosclerosis.

External regulation of inflammatory signals





HGF suppresses inflammatory responses in EC







Tubulogenesis by epithelial cells
Angiogenesis by endothelial cells
Scattering
Invasion and metastasis

HGF; hepatocyte growth factor





HGF inhibits VEGF-stimulated leukocyte adhesion & CAM expression in HUVECs



HGF suppresses VEGF-induced transcriptional activity through inhibition of NF- κ B activation




HGF inhibits VEGF-induced NF- κ B activation through inhibition of I κ B- α phosphorylation and degradation




HGF inhibits VEGF-induced leukocyte infiltration *in vivo*


A



B



C



Co-treatment of HGF with VEGF shows the synergistic effect on neovessel formation in the mouse skin

CTL



VEGF







HGF




VEGF+HGF



**PECAM-1
(x200)**



VEGF and HGF synergistically stimulates angiogenesis






1. Xin X, Yang S, Ingle G, Zlot C, Rangell L, Kowalski J, Schwall R, Ferrara N, Gerritsen ME. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. *Am J Pathol.* 2001; 158: 1111–1120.
2. Mary E. Gerritsen, **HGF and VEGF: A Dynamic Duo**, *Circ. Res.* 2005 96: 272-273.





**Therapeutic angiogenesis using VEGF & HGF co-administration
may be more clinically applicable
Reduce inflammation & potentiate angiogenesis**

Internal regulation of inflammatory signals



ERK suppresses inflammatory responses in EC




ERK negatively regulates VEGF-induced VCAM-1 expression in ECs




ERK negatively regulates VEGF-Induced transcriptional activity of VCAM-1






B







Inhibition of ERK increases VEGF-induced I κ B- α phosphorylation and NF- κ B activation








PKC mediates both ERK and NF- κ B activation in response to VEGF




ERKs inhibit IL-1 β - and TNF- α -induced CAM expression via inhibition of the NF- κ B pathway in EC




ERK inhibits inflammatory cytokine-induced leukocyte adhesion to ECs



Schematic pathway for the negative regulation of VEGF-induced VCAM-1 expression by ERK



Balanced Regulation of **Angiogenesis** & **Inflammation** in the vascular wall



Acknowledgement

Vascular genomics laboratory



Yonsei University

Jeong-Ki Min, Ph. D.

Yong-Sun Maeng

Kangwon National University

Young-Myeong Kim, Ph. D.

Young-Mi Kim, Ph.D

Ewha Women's University

Goo-Taeg Oh, Ph. D.